Safety of selective androgen receptor modulators
Its usually worst during dose escalation and tends to improve as your body adapts
So, most people are deficient without knowing
We also report that 13% of patients with type 1 diabetes in our registry use adjuvant glucose-lowering therapy in addition to insulin, significantly higher than the 5.4% reported from the T1D Exchange Registry in the US [18]
In contrast, when discussing tirzepatide vs retatrutide, it is notable that retatrutide is a novel triple agonist that activates GLP-1, GIP, and glucagon receptors
The Phase II trial for retatrutide reported some adverse events: A large percentage of participants (73% to 94%) reported side effects while taking retatrutide, especially in the higher 8-mg and 12-mg groups